Flora Szeri

Dr. Flora Szeri

Institute of Enzymology, Research Center for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
RJRobert S. Jansen
Robert S. Jansen
SDSuzanne Duijst
Suzanne Duijst
SMSunny Mahakena
Sunny Mahakena
DSDaniela Sommer
Daniela Sommer
Flora SzeriFlora Szeri
Flora Szeri
KWKoen van de Wetering
Koen van de Wetering
Objective—: Mutations in ABCC6 underlie the ectopic mineralization disorder pseudoxanthoma elasticum (PXE) and some forms of generalized arterial calcification of infancy, both of which affect the cardiovascular system. Using cultured cells, we recently showed that ATP-binding cassette subfamily C member 6 (ABCC6) mediates the cellular release of ATP, which is extracellularly rapidly converted into AMP and the mineralization inhibitor inorganic pyrophosphate (PP i ). The current study was performed to determine which tissues release ATP in an ABCC6-dependent manner in vivo, where released ATP is converted into AMP and PP i , and whether human PXE ptients have low plasma PP i concentrations. Approach and Results—: Using cultured primary hepatocytes and in vivo liver perfusion experiments, we found that ABCC6 mediates the direct, sinusoidal, release of ATP from the liver. Outside hepatocytes, but still within the liver vasculature, released ATP is converted into AMP and PP i . The absence of functional ABCC6 in patients with PXE leads to strongly reduced plasma PP i concentrations. Conclusions—: Hepatic ABCC6-mediated ATP release is the main source of circulating PP i , revealing an unanticipated role of the liver in systemic PP i homeostasis. Patients with PXE have a strongly reduced plasma PP i level, explaining their mineralization disorder. Our results indicate that systemic PP i is relatively stable and that PXE, generalized arterial calcification of infancy, and other ectopic mineralization disorders could be treated with PP i supplementation therapy.

1 April 2003 in Toxicology Letters
Verified
Journal Article
Closed access
ABAdrienn Bodó
Adrienn Bodó
ÉBÉva Bakos
Éva Bakos
Flora SzeriFlora Szeri
Flora Szeri
AVAndrás Váradi
András Váradi
BSBalázs Sarkadi
Balázs Sarkadi

1 June 2003 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ABAdrienn Bodó
Adrienn Bodó
ÉBÉva Bakos
Éva Bakos
Flora SzeriFlora Szeri
Flora Szeri
AVAndrás Váradi
András Váradi
BSBalázs Sarkadi
Balázs Sarkadi
The multidrug resistance proteins MRP2 (ABCC2) and MRP3 (ABCC3) are key primary active transporters involved in anionic conjugate and drug extrusion from the human liver. The major physiological role of MRP2 is to transport conjugated metabolites into the bile canaliculus, whereas MRP3 is localized in the basolateral membrane of the hepatocytes and transports similar metabolites back to the bloodstream. Both proteins were shown to interact with a large variety of transported substrates, and earlier studies suggested that MRPs may work as co-transporters for different molecules. In the present study we expressed the human MRP2 and MRP3 proteins in insect cells and examined their transport and ATPase characteristics in isolated, inside-out membrane vesicles. We found that the primary active transport of estradiol-17-β-d-glucuronide (E217βG), a major product of human steroid metabolism, was differently modulated by bile acids and organic anions in the case of human MRP2 and MRP3. Active E217βG transport by MRP2 was significantly stimulated by the organic anions indomethacin, furosemide, and probenecid and by several conjugated bile acids. In contrast, all of these agents inhibited E217βG transport by MRP3. We found that in the case of MRP2, ATP-dependent vesicular bile acid transport was increased by E217βG, and the results indicated an allosteric cross-stimulation, probably a co-transport of bile acids and glucuronate conjugates through this protein. There was no such stimulation of bile acid transport by MRP3. In conclusion, the different transport modulation of MRPs by bile acids and anionic drugs could play a major role in regulating physiological and pathological metabolite fluxes in the human liver.

12 July 2017 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
DDDóra Dedinszki
Dóra Dedinszki
Flora SzeriFlora Szeri
Flora Szeri
EKEszter Kozák
Eszter Kozák
VPViola Pomozi
Viola Pomozi
NTNatália Tőkési
Natália Tőkési
AVAndrás Váradi
András Váradi
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

8 July 2020 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
Flora SzeriFlora Szeri
Flora Szeri
SLStefan Lundkvist
Stefan Lundkvist
SDSylvia Donnelly
Sylvia Donnelly
UEUdo F. H. Engelke
Udo F. H. Engelke
KRKyu Rhee
Kyu Rhee
KWKoen Van De Wetering
Koen Van De Wetering
The membrane protein ANKH was known to prevent pathological mineralization of joints and was thought to export pyrophosphate (PPi) from cells. This did not explain, however, the presence of ANKH in tissues, such as brain, blood vessels and muscle. We now report that in cultured cells ANKH exports ATP, rather than PPi, and, unexpectedly, also citrate as a prominent metabolite. The extracellular ATP is rapidly converted into PPi, explaining the role of ANKH in preventing ankylosis. Mice lacking functional Ank (Ankank/ank mice) had plasma citrate concentrations that were 65% lower than those detected in wild type control animals. Consequently, citrate excretion via the urine was substantially reduced in Ankank/ank mice. Citrate was even undetectable in the urine of a human patient lacking functional ANKH. The hydroxyapatite of Ankank/ank mice contained dramatically reduced levels of both, citrate and PPi and displayed diminished strength. Our results show that ANKH is a critical contributor to extracellular citrate and PPi homeostasis and profoundly affects bone matrix composition and, consequently, bone quality. Biallelic inactivating mutations in the progressive ankylosis gene (ANKH/Ank, humans/mice) cause a severe form of arthritis, primarily affecting joints of hands, feet and the spine. Low extracellular concentrations of the mineralization inhibitor pyrophosphate underlie the joint calcification in mice and humans that are devoid of functional Ank or ANKH, respectively. It was previously thought that ANKH mediates the release of pyrophosphate from the cytosol to the extracellular environment. We here show, however, that PPi is formed in the extracellular environment by Ectonucleotide Pyrophosphatase Phosphodiesterase 1 (ENPP1), from ATP released via ANKH. Untargeted metabolomics further revealed that ANKH provides a pathway for the release of nucleoside triphosphates in general and, unexpectedly, the Krebs-cycle intermediate citrate. Mice lacking Ank activity (Ankank/ank mice), have substantially reduced concentrations of citrate in their plasma and urine. Citrate was even undetectable in urine of a human patient lacking functional ANKH. Bones of Ankank/ank mice have reduced mechanical strength and their bone matrix contains dramatically reduced levels of PPi and citrate. Our data demonstrate that ANKH/Ank crucially contributes to the disposition of citrate and PPi in vivo and profoundly affects bone quality. Extracellular citrate is ubiquitous, and additional phenotypes are therefore expected to be associated with absence of Ank activity.

18 January 2019 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
MBMagnus Bäck
Magnus Bäck
TATamas Aranyi
Tamas Aranyi
LCLeonor Cancela
Leonor Cancela
MCMiguel Carracedo
Miguel Carracedo
NCNatércia Conceição
Natércia Conceição
Hervé KempfHervé Kempf
Hervé Kempf
The physicochemical deposition of calcium-phosphate in the arterial wall is prevented by calcification inhibitors. Studies in cohorts of patients with rare genetic diseases have shed light on the consequences of loss-of-function mutations for different calcification inhibitors, and genetic targeting of these pathways in mice have generated a clearer picture on the mechanisms involved. For example, generalized arterial calcification of infancy (GACI) is caused by mutations in the enzyme ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (eNPP1), preventing the hydrolysis of ATP into pyrophosphate (PPi). The importance of PPi for inhibiting arterial calcification has been reinforced by the protective effects of PPi in various mouse models displaying ectopic calcifications. Besides PPi, Matrix Gla Protein (MGP) has been shown to be another potent calcification inhibitor as Keutel patients carrying a mutation in the encoding gene or Mgp-deficient mice develop spontaneous calcification of the arterial media. Whereas PPi and MGP represent locally produced calcification inhibitors, also systemic factors contribute to protection against arterial calcification. One such example is Fetuin-A, which is mainly produced in the liver and which forms calciprotein particles (CPPs), inhibiting growth of calcium-phosphate crystals in the blood and thereby preventing their soft tissue deposition. Other calcification inhibitors with potential importance for arterial calcification include osteoprotegerin, osteopontin, and klotho. The aim of the present review is to outline the latest insights into how different calcification inhibitors prevent arterial calcification both under physiological conditions and in the case of disturbed calcium-phosphate balance, and to provide a consensus statement on their potential therapeutic role for arterial calcification.